Boone Capital Management tossed a few million at Tyra Biosciences. Ten and change, to be precise. That’s 398,482 shares, if you’re counting. The kind of move that either signals brilliance or a slow descent into wishful thinking. February 17th, 2026. Mark the date. It might be a footnote, or it might be the start of something… interesting.
The Play
The SEC filing landed like a damp cigarette. Boone Capital, they’re suddenly interested in Tyra. A $10.48 million stake, acquired in the last quarter. It’s the kind of money that buys a decent-sized headache, or, in this case, a piece of a biotech firm that’s still mostly promise and very little profit. They own 3.3% of the fund’s reported holdings. A rounding error for some, a calculated risk for others.
What They’re Holding
- MDT: $41.19 million. Solid. Predictable. Like a well-worn shoe.
- MIRM: $33.27 million. Another brick in the wall.
- IONS: $33.05 million. Still breathing.
- CI: $26.55 million. Steady, if unremarkable.
- BMRN: $24.48 million. Holding the line.
Compared to that lot, Tyra is a long shot. Shares were trading at $38.67 on Friday. Up 253% in a year. That’s the kind of jump that makes accountants nervous and gamblers ecstatic. The S&P 500? A polite 16%. Tyra is either a rocket or a firecracker.
The Company, Briefly
Tyra Biosciences. They tinker with cancer. Targeted therapies, specifically. Focusing on FGFR3 inhibition for bladder cancer, among other things. Preclinical stage, which means they’re still mostly drawing pictures and hoping for the best. They’re banking on a platform called SNAP. Sounds like a quick decision, doesn’t it? They want to license their discoveries, collect milestone payments, and eventually, if the gods are kind, sell something.
| Metric | Value |
|---|---|
| Price (as of Friday) | $38.67 |
| Market Capitalization | $2.1 billion |
| Net Income (TTM) | ($119.95 million) |
What It Means (If Anything)
Momentum like that usually scares off the sensible types. But in biotech, a big move can sometimes mean someone sees something the rest of us don’t. Or they’re just playing a longer game. Tyra isn’t a concept anymore, not entirely. They’re narrowing their focus, running three Phase 2 trials. Discipline is good. Especially when you’re burning through cash. They ended the year with around $256 million. Enough runway to get through at least 2027. Assuming they don’t hit a wall.
Losses are significant, nearly $120 million for the year. But that’s the price of ambition. Compared to Boone’s safer bets, Tyra is a gamble. A calculated one, perhaps. Shares jumped 47% since the last quarter. For now, the house is winning. But the game isn’t over. Not by a long shot.
Read More
- Seeing Through the Lies: A New Approach to Detecting Image Forgeries
- Staying Ahead of the Fakes: A New Approach to Detecting AI-Generated Images
- Julia Roberts, 58, Turns Heads With Sexy Plunging Dress at the Golden Globes
- Gold Rate Forecast
- Unmasking falsehoods: A New Approach to AI Truthfulness
- Palantir and Tesla: A Tale of Two Stocks
- Smarter Reasoning, Less Compute: Teaching Models When to Stop
- How to rank up with Tuvalkane – Soulframe
- TV Shows That Race-Bent Villains and Confused Everyone
- Celebs Who Narrowly Escaped The 9/11 Attacks
2026-03-20 19:03